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Edited by Sandro SonninoAbstract The formation of inclusion bodies in dopaminergic
neurons is associated with the pathogenesis of Parkinsons
disease. In order to clarify the role of dopamine/L-dopa in the
formation of protein aggregates, we investigated dopamine/L-
dopa-related aggregation using an experimental inclusion model.
The inhibition of tyrosine hydroxylase (TH) by a-methyltyrosine
dramatically decreased MG132-induced aggregate formation. In
addition, the inhibition of TH caused the upregulation of protea-
somes in cultured cells and the dopamine/L-dopa induced non-
enzymatic polymerization of ubiquitin. This inhibition did not
aﬀect cell viability. These results suggest that dopamine/L-dopa
might enhance aggregate formation, and that intracellular aggre-
gates may not be toxic to cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Lewy body (LB) formation in dopaminergic neurons in the
substantia nigra is one of the most characteristic ﬁndings in
the Parkinsons disease (PD) brain [1]. Intracellular inclusion
bodies in neurodegenerative diseases suggests the molecular
components that may be associated with the pathogenesis [1–
3]. Ubiquitin and a-synuclein are well known components of
LBs and their presence implies the importance of the ubiqui-
tin-proteasome system in the formation of LBs [2,4,5]. How-
ever, the formation of LBs primarily in dopaminergic
neurons has not been addressed. Recent reports suggest that
a-synuclein may be toxic in dopaminergic neurons, and trophic
in non-dopaminergic neurons [6]. This toxicity may be due to
the formation of protoﬁbrils by a-synuclein, which are more
toxic than ﬁbrils, in the presence of L-dopa/dopamine [7].
Although this observation may oﬀer insight into dopaminergic
neuron-speciﬁc toxicity in the pathogenesis of PD, it seems
contrary to the observation of LBs in dopaminergic neurons,
and that intracellular inclusion bodies are not toxic to the cells
[8,9].Abbreviations: DMEM, Dulbeccos Modiﬁed Eagle Medium; SDS,
sodium dodecyl sulfate; PMSF, phenylmethylsulfonyl ﬂuoride; EDTA,
ethylenediaminetetraacetic acid; CBB, coomassie brilliant blue
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doi:10.1016/j.febslet.2004.12.091The proteasome is a large multicatalytic protease that is
responsible for the majority of intracellular protein degrada-
tion [10,11]. The application of excess dopamine induces a
time- and dose-dependent reduction of proteasome activity
in neural PC12 cells [12]. Therefore, in order to promote fur-
ther understanding of aggregates and the pathogenesis of
PD, the association between L-dopa/dopamine and protein
aggregation should be examined. We hypothesized that L-
dopa/dopamine might aﬀect ubiquitin-proteasome system-re-
lated aggregates formation. In the present report, we examine
the association of L-dopa/dopamine with the formation of
intracellular inclusion bodies through an experimental inclu-
sion model in PC12 cells.2. Materials and methods
2.1. Chemicals and antibodies
Nerve growth factor (NGF) was purchased from Invitrogen (CA).
MG132 and a-methyltyrosine (aMT) were purchased from Calbio-
chem (Germany) and PFALTZ&BAUER (Germany), respectively.
Tyrosine, L-dopa, dopamine, and 3-(4,5-dimethylthiazol-2-yl)2,5-di-
phenyl tetrasolium bromide (MTT) were obtained from Wako (Osaka,
Japan). Kojic acid, benserazide hydrochloride, fusaric acid, reserpine,
ubiquitin protein, and anti-c tubulin (GTU-88) were purchased from
Sigma (St. Louis). Antibodies against a-synuclein (C-20) and ubiquitin
(FL-76) were purchased from Santa Cruz (SantaCruz, CA). Tyrosine
hydroxylase (TH) antibody was from Cell Signaling Lab (Beverly). An-
other anti-ubiquitin antibody, FK1, was kindly provided by Dr.
Fujimuro at Hokkaido University. Horse-radish-peroxidase (HRP)-
linked anti-goat IgG, biotin-linked anti-mouse IgM, and FITC- or
TR-conjugated secondary antibodies for immunohistochemistry were
from Santa Cruz. HRP-linked anti-rabbit IgG and HRP-conjugated
streptoavidin were from Amersham. Z–Leu–Leu–Leu–MCA and Z–
Arg–Arg–MCA, substrates for proteasome and cathepsin B, respec-
tively, were obtained from Peptide Institute INC (Japan).
2.2. Cell culture
PC12 cells were maintained at 37 C in 5% CO2 in DMEM/F12 med-
ium, supplemented with 5% fetal bovine serum and 1% penicillin/strep-
tomycin. Immunohistochemical experiments were carried out using
8-well chamber slides containing 200–500 cells/well. For immunoblot-
ting, 6-well plates containing 105 cells/well were used. Neurally diﬀer-
entiated PC12 cells were established by treating with 50 ng/ml of
NGF for 5–6 days. The proteasome inhibitor, MG132, was prepared
as a 1 mM stock solution in ethyl alcohol, and diluted in the medium
prior to addition to the cells. The MG132 medium was added to PC12
cells treated with NGF for 5 days, bringing the ﬁnal concentrations to
250 nM MG132 and 50 ng/ml of NGF. After 24 or 48 h, treated cells
were analyzed. For the inhibition of TH, 1–100 lg/ml of aMT was
added with MG132, simultaneously. Other enzyme inhibitors were also
added simultaneously with MG132. In order to investigate the eﬀects
of tyrosine, L-dopa, and dopamine, cells were treated with 10 lM of
each as a ﬁnal concentration.blished by Elsevier B.V. All rights reserved.
Fig. 1. Characterization of the intracellular aggregate model in PC12
cells. (A–C) Neurally diﬀerentiated PC12 cells without MG132
treatment. (D–I) Neurally diﬀerentiated PC12 cells treated with 250
nM MG132 for 24 h. (A,D) Stained with a-synuclein antibody (green),
(B,E) ubiquitin antibody (red), (C,F) merged image of a-synuclein and
ubiquitin. a-synuclein and ubiquitin positive aggregates are observed
in the perinuclear portion 24 h after MG132 treatment. (G–I) This
intracellular aggregate (arrow) is tubulin positive as well as ubiquitin.
(G) c tubulin (green), (H) ubiquitin (red), and (I) merged image of
tubulin and ubiquitin. Scale bar = 10 lm.
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For immunoﬂuorescent staining, 4% paraformaldehyde-ﬁxed PC12
cells were washed with PBS, and were incubated with ice-cold solution
containing 95% ethyl alcohol and 1% acetic acid for 5 min. After wash-
ing with PBS twice, the cells were incubated with antibodies overnight
at 4 C. Then, the cells were washed with PBS twice, and incubated
with FITC- or TR-conjugated secondary antibody at room tempera-
ture for 4 h. Cells were washed with PBS several times, and, ﬁnally,
the slides were covered using Vectashield (Vector Lab Inc, Burlin-
game). The number of cells including aggregates was counted under
immunoﬂuorescent microscopy.
2.4. Preparation of the TH-promoter-pEGFP construct and transfection
The rat TH-promoter was cloned by PCR using the genome from
PC12 cells as a template. Primers sets designed for cloning 4.2 kb up-
stream of TH promoter were Fw5 0-CAGAGAAAGTAGATGAGAG-
ATGC-3 0 and Rev5 0-GTGGTCCCGGGTTCTGTCTCCACAG-3 0.
The underlined G is to establish an artiﬁcial EcoRI restriction site.
Ampliﬁed promoter DNA was cloned by insertion into the pGEM-T
easy vector (Promega, Madison), and then transferred to the pro-
moter-less pEGFP-1 vector (Clontech). Transfection of these vectors
was carried out using TransFast transfection Reagent (Promega) fol-
lowing the manufacturers protocol.
2.5. Immunoblot analysis
For immnoblotting, NGF-treated PC12 cells were harvested from 6-
well culture plates, and were lysed in SDS-sample buﬀer (50 mM Tris–
HCL, pH 6.8, 2% SDS, 10% glycerol, 1 mM PMSF, 2 mM EDTA) by
gentle pipetting in the tube, and denatured by incubating at 95 C for
5 min. Dye and 2-mercaptoethanol were added to the specimens and
the mixture was heated at 95 C just before SDS–PAGE. 20 lg ali-
quots were used for SDS–PAGE. Proteins were separated by size on
10% or 13% acrylamide gels, transferred onto PVDF membrane (Hy-
bond-P; Amersham) and hybridized with the required antibody in
PBS-Tween20 at room temperature for 1 h. The immunoreactive signal
was detected using HRP-linked anti-rabbit IgG and ECL detection re-
agent (Amersham).
2.6. Analyses of proteasome and cathepsin activities
The activities of proteasome and cathepsin B were determined by
measuring the cleavage rate of Z–Leu–Leu–Leu–MCA and Z–Arg–
Arg–MCA, respectively. Each ﬂuorogenic substrate was prepared as
a 10 mM stock in DMSO. For the analysis of proteasome activity, cul-
tured cells (106) were lysed in proteolysis buﬀer-A (10 mM Tris–HCl,
pH 7.8, 0.5 mM dithiothreitol, 5 mM ATP, 5 mM MgCl2, and 0.1%
Triton-X100) for the time indicated in the ﬁgure legend. For the anal-
yses of cathepsin activity, cells were lysed in proteolysis buﬀer-B
(Hanks balanced salt solution lacking sodium bicarbonate, but con-
taining 0.6 mM CaCl2, 0.6 mM MgCl2, 2 mM L-cystein, 25 mM
PIPES, pH 7.0, and 0.1% Triton-X100). Prepared lysates and 2.5 ll
of the substrate were mixed in 96 well plate, and incubated at 37 C
for 30 min. Fluorescence was measured at ex 355 nm/em 460 nm using
an ARVOMX 1420 multilabel counter (Perkin–Elmer) and compen-
sated by protein concentration.
2.7. In vitro aggregation analyses
For in vitro aggregation analyses, a mixture of 1 mg/ml ubiquitin, 10
mM Tris–HCl, pH 7.9, and 10 lM dopamine or L-dopa was incubated
at 30 C for 12 h. Polymerization of ubiquitin was detected by CBB
staining and immunoblotting using FK1 antibody.
2.8. MTT assay
For the analyses of cell viability, 5 · 103 cells in 96-well ﬂat bottomed
culture plates were subjected to an MTT assay according to the manu-
facturers protocol with some modiﬁcations. Brieﬂy, treated cells were
incubated with 100 ll ofMTT solution for 4 h, followed by the addition
of 100 ll of isopropylalcohol including 0.04 N HCl. After mixing thor-
oughly by repeated pipetting, the absorbance was measured at 600 nm.
2.9. Statistical analyses
The quantitative data were assessed using ANOVA in the StatView
software system. The criterion for statistical signiﬁcance was P < 0.05.3. Results
3.1. Characterization of the intracellular inclusion model
The proteasome inhibitor, MG132 (250 nM), induced intra-
cellular aggregates in NGF-diﬀerentiated PC12 cells (Fig. 1).
Ubiquitin and a-synuclein-positive small aggregates were ob-
served in a perinuclear region at 24 h after MG132 administra-
tion (Fig. 1D–F). Further, larger aggregates were observed at
48 h after MG132 administration (data not shown). These
aggregates expressed tubulin immunoreactivity (Fig. 1G and
I), suggesting that they were similar in composition proteins
to aggresomes reported by Kopito. As reported previously,
the number of cells containing aggregates at 24 h after
MG132 administration were 78% under 100 nM MG132 and
82% under 250 nM MG132 [8]. In this inclusion model, up
to 5% of cells show apoptotic cell death. Another proteasome
inhibitor, PSI (Z–Ile–Glu(Obut)–Ala–Leu–H(aldehyde)), also
induced similar structures (data not shown).3.2. Decreased aggregate formation by TH inhibition
In this experimental model, the degree of aggregate forma-
tion diﬀered between cells. We established TH-promoter (4.2
kb)-including pEGFP-1 vector-transfected PC12 cells, which
can be easily assayed for TH activity (Fig. 2A and B). The
TH expression level is diﬀerent for each cell and we investi-
Fig. 2. TH inhibition decreases MG132-induced aggregate formation. (A,B) TH-promoter-inserted pEGFP vector shows green ﬂuorescence in
neurally diﬀerentiated PC12 cells. (C,D) The cell with densed green ﬂuorescence (arrow) shows abundant ubiquitin-positive aggregates (red)
compared to the cells with weak green ﬂuorescent signal at 24 h after MG132 (250 nM) treatment. (E) Ubiquitin-positive aggregates are observed in
the cells at 24 h after MG132 treatment. (F) Simultaneous aMT (100 lM) treatment with MG132 inhibits aggregate formation. Scale bar in A–F
corresponds to 10 lm. (G) Number of the cells with aggregates. Inhibitory eﬀect of aMT on aggregate formation is statistically signiﬁcant (\) and
shows a dose-dependent manner. The percentage of each column: 0 lM; 85.4 ± 4.1, 1 lM; 71.3 ± 5.2, 10 lM; 36.5 ± 3.0, and 100 lM; 34.5 ± 6.6. The
average ± S.E. of 6–7 independent experiments are shown. (H) Immunoblot using ubiquitin antibody. 1: No MG132 treatment (vehicle). 2: Treated
with 250 nM MG132 for 24 h. 3: Treated with 250 nM MG132 and 100 lM aMT for 24 h. aMT treatment decreases MG132-induced
polyubiquitination.
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cells with a high EGFP signal, more aggregates were formed
compared with that in low EGFP-expressed cells (Fig. 2C
and D). From this observation, we hypothesized that TH inhi-
bition may inhibit aggregate formation.
In order to clarify this point, inhibitory experiments using
several enzyme inhibitors were performed. Simultaneous
aMT (10 lM), a competitive inhibitor of TH, treatment with
MG132 dramatically decreased aggregate formation in a dose
dependent manner under proteasome inhibition (Fig. 2E–G).
On the other hand, benserazide (an inhibitor of aromatic
l-aminoacid decarboxylase), fusaric acid (an inhibitor of dopa-
mine beta-hydroxylase), and kojic acid (an inhibitor of tyrosi-
nase) did not decrease aggregate formation (Fig. 3A–G).
Further, reserpine, a drug that interferes with the vesicular
storage of cathecholamine, did not inhibit the MG132-induced
aggregate formation. On the contrary, reserpine occasionally
induced huge aggregates in the perinuclear portion (Fig. 3H).
Furthermore, the addition of L-dopa and/or dopamine under
the inhibition of TH by aMT canceled the inhibitory eﬀect
of aMT (Fig. 3F and G). Although the percentage of the cells
with aggregates under simultaneous aMT (10 lM) treatment
with MG132 was 36.5%, 10 lM L-dopa and dopamine in-
creased the percentage to 58.1% and 64.5%, respectively. Nor-
epinephrine demonstrated a similar eﬀect, but less than that of
L-dopa/dopamine (data not shown).
Immunoblot analyses using ubiquitin antibodies showed a
reduced high molecular weight smear after aMT administra-tion (Fig. 3H). On the other hand, other enzyme inhibitors
such as benserazide did not decrease this ubiquitin smear.
However, aMT did not alter a-synuclein polymerization (data
not shown).
3.3. Eﬀect of aMT on proteasome and cathepsin B activity
To investigate the eﬀect of aMT on the activities of protea-
some and cathepsin B, the enzyme activity of each proteolytic
enzyme was measured. Although MG132 administration de-
creased proteasome activity, TH inhibition by aMT adminis-
tration increased proteasome activity slightly (Fig. 4A and
B). Cathepsin B activity was increased by proteasome inhibi-
tion. However, an additional administration of aMT downreg-
ulated cathepsin B activity (Fig. 4C).
3.4. L-dopa and dopamine induce ubiquitin polymerization in
vitro
In order to investigate the eﬀects of L-dopa and dopamine
on ubiquitin polymerization, a simple experiment using ubiqui-
tin and L-dopa or dopamine without ATP or other related
molecules was performed. Surprisingly, in this quite simple
condition, L-dopa and dopamine induced ubiquitin polymeri-
zation (Fig. 5A). Further, this polymerized ubiquitin was
detectable by ubiquitin and FK1 antibodies (Fig. 5B). These
results suggest that novel mechanisms of ubiquitin polymeriza-
tion mediated by L-dopa and dopamine may exist, which do
not require energy or other related molecules, such as ubiquitin
ligase.
Fig. 3. Several enzyme inhibitors except aMT do not inhibit the
formation of MG132-induced ubiquitin-positive aggregates. Scale
bar = 10 lm. (A) 24 h after MG132 (250 nM) treatment. (B) MG132
and aMT (10 lM) treatment. (C) MG132 and benserazide (20 lM),
(D) MG132 and fusaric acid (20 lM), (E) MG132 and kojic acid
(20 lM), (F) MG132, aMT, and 10 lM L-dopa, (G) MG132, aMT
and 10 lM dopamine. L-dopa and dopamine cancel the inhibitory
eﬀect of aMT on aggregate formation. (H) MG132 and reserpine
(1 lM). Huge aggregates are shown in the perinuclear part (arrow
head).
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Fig. 4. aMT increases proteasome activity and decreases cathepsine B
activity. (A) aMT increases proteasome activity. Upregulation of
proteasome activity by aMT (6 h) is dose dependent. The percentage of
each column: 0 lM; 100.0 ± 0.9, 1 lM; 156.8 ± 3.0, 10 lM;
180.1 ± 5.0, and 100 lM; 181.1 ± 5.4. (B) Slight increase of proteasome
activity by aMT (10 lM) under MG132 (250 nM)-treated condition.
The percentage of each column is no treat; 100.0 ± 1.8, MG132;
88.2 ± 4.6, MG132 plus aMT; 93.0 ± 3.8. (C) Cathepsin B activity is in
contrast to proteasome. The experiment condition is same as B. The
percentage of each column: no treat; 100.0 ± 1.3, MG132; 186.8 ± 4.9,
MG132 plus aMT; 124.0 ± 1.2. \: Statistically signiﬁcant.
Fig. 5. L-dopa/dopamine enhance the ubiquitin polymerization in
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In order to clarify the role of L-dopa/dopamine-related
aggregate enhancement on cell death under decreased protea-
some activity, a viability assay was carried out using the
MTT system. In our experiments, MG132 produced dose-
dependent cell death at 24 h after administration. However,
aMT did not show either a toxic eﬀect or a protective eﬀect
(Fig. 6).vitro. (A) SDS–PAGE (CBB staining). (B) Immunoblotting using FK1
antibody. 1: Ubiquitin only. 2: Ubiquitin and L-dopa (10 lM), 3:
Ubiquitin and dopamine (10 lM). Lane 2 and 3 show enhanced
ubiquitin polymerization by L-dopa/dopamine.4. Discussion
Several previous reports have implicated dopamine and/or
L-dopa in the cell death observed in PD [6,13,14]. Although
the direct mechanisms of selective vulnerability of dopaminer-
gic neurons in PD has not been clariﬁed, some reports suggestthat dopamine/L-dopa-induced oxidative stress [15] and the
co-existence dopamine/L-dopa with a-synuclein may produce
harmful eﬀects in dopaminergic cells [6]. In the same way,
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Fig. 6. Cell viability assay using the MTT system. No signiﬁcant
diﬀerences in cell viability between 0, 10 or 100 lM aMT in each
concentration of MG132.
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rons is one of the most characteristic pathological ﬁndings for
PD. However, the detailed mechanisms of LB formation ob-
served primarily in dopaminergic neurons is not understood.
In this study, we investigated the association between protein
aggregation and dopamine/L-dopa.
We have reported this experimental inclusion model previ-
ously [8]. In this model, perinuclear aggregates are formed that
are immunopositive for p62, tubulin, a-synuclein, and ubiqui-
tin. Although approximately 80% of the cells show aggregates
at 24 h after MG132 treatment, the size and number of aggre-
gates in the cells may be diﬀerent. Since PC12 cells express
abundant TH, they will transcribe the 4.2 kb of TH pro-
moter-inserted pEGFP vector, and express the marker green
ﬂuorescence (Fig. 2). Interestingly, cells expressing dense green
ﬂuorescence have more and larger aggregates compared to
cells that express slight ﬂuorescence (Fig. 2). Therefore, we
hypothesized that TH activity aﬀects the formation of aggre-
gates under proteasome inhibition. Indeed, it has been re-
ported that dopamine induces proteasome inhibition in PC12
cells [12].
In order to clarify this point, we performed inhibitory exper-
iments using aMT, a competitive inhibitor of TH [16]. aMT
has been reported to decrease dopamine levels in PC12 cells
via TH inhibition. Indeed, aMT, but not other enzyme inhib-
itors such as benserazide, dramatically decreased aggregate
formation. From the converse eﬀect of additional dopamine
and L-dopa on this condition, dopamine and L-dopa may en-
hance aggregate formation under proteasome inhibition. Re-
sults from inhibitory experiments (Fig. 3H) using reserpine
also support this hypothesis. However, the aggregate forma-
tion induced simply by L-dopa or dopamine without MG132
could not be observed (data not shown).
Additional excess extracellular dopamine has been reported
to inhibit proteasome activity [12]. Consistent with those re-
sults, we found that TH inhibition slightly increased protea-
some activity and decreased cathepsin B activity (Fig. 4).
However, the eﬀect on proteasome activity by aMT was slight.
Therefore, further mechanisms that enhance aggregate forma-tion are predicted. In the present study, L-dopa/dopamine eas-
ily polymerized ubiquitin non-enzymatically in vitro. Although
the detailed mechanism of this phenomenon has not been clar-
iﬁed, it seems to be associated with the observation of ubiqui-
tin-positive aggregates primarily in dopaminergic cells. L-dopa
and dopamine easily change their structure to several metabo-
lites, such as dopaquinone, which may be related to our in vi-
tro observations [17].
It has been reported that dopamine/L-dopa inhibits the con-
version of protoﬁbrils to ﬁbrils via the formation of a dopa-
mine-a-synuclein adduct [7]. Protoﬁbrils of a-synuclein may
be pathogenic and the ﬁbrils are inert or even protective in
dopaminergic cells. However, in practice, Lewy bodies are ob-
served primarily in dopaminergic neurons in the substantia ni-
gra. These events are seems to be paradoxical, and other
factors should be considered to fully explain these observa-
tions. Our observation that dopaminergic cells easily form
the ubiquitin-related aggregates can explain this paradoxical
problem.
In the present study, TH inhibition did not alter cell viabil-
ity. However, recent reports suggest that the formation of
intracellular inclusion bodies results in the sequestration of
proteins that are unnecessary or toxic for cell survival. Based
on this hypothesis, aggregate formation in PC12 cells may be
a result of the sequestration of unnecessary proteins including
a-synuclein protoﬁbril to avoid toxic insults.
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